Global Acquired Hemophilia Treatment Market Is Expected To Reach USD 2,474.7 Mn By 2023

The latest market report published by Brisk Insights “Global Acquired Hemophilia Treatment Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 - 2023,” the acquired hemophilia treatment market was valued at USD 1,923.4 Mn in 2015, and is expected to reach USD 2,474.7 Mn by 2023, expanding at a CAGR of 3.2% from 2016 to 2023.

Browse the full report Acquired Hemophilia Treatment Market - Growth, Future Prospects, Competitive Analysis, 2016 – 2023 at https://www.briskinsights.com/report/acquired-hemophilia-treatment-market

Market Insights

According to National Organization of Rare Disorders (NORD), acquired hemophilia is a rare autoimmune disorder characterized by bleeding that occurs in patients with a personal and family history negative for hemorrhages. In acquired hemophilia, the body produces antibodies that attack clotting factors, most often factor VIII. Medical practitioners suggest that, acquired hemophilia can potentially cause life-threatening bleeding complications in severe cases and in around 50% of cases, there is an identifiable underlying clinical condition; in the other 50% no cause is known i.e. idiopathic. Treatment strategies that are applied against acquired hemophilia are based on two major objectives. The primary objective is effective control of bleeding manifestations during acute bleeding episodes. The secondary and ultimate therapeutic objective is to eliminate the inhibitor and cure the disease. Thus, the global acquired hemophilia treatment market on the basis of therapeutics has been segmented into two major categories such as traditional therapies and advanced therapies. The traditional therapies are further sub-categorized into steroid treatment, cytotoxic treatment and immunomodulatory treatment. The advanced therapies is further segmented into Desmopressin, Recombinant Activated Factor VII/NovoSeven, Recombinant Activated Factor VIII/Obizur, and Activated Prothrombin Complex Concentrate (aPCC)/ FEIBA. The advanced therapies held the largest segment due to introduction of novel therapies for the treatment of acquired hemophilia.

Geographically in 2015, constituted by regional markets of U.S. and Canada; North America stood out to be the clear leader in the global acquired hemophilia treatment market. North America dominated the market due to aging population, high awareness associated with hemophilia and types in people, and developed healthcare infrastructure. Moreover, in U.S. and Canada, the network of hemophilia care centers is well set with domestic government support. The primary management option is evolved in developed countries with early treatment of bleeding episodes and quick home therapy. Asia Pacific was observed as the attractive market in acquired hemophilia treatment due to emerging healthcare infrastructure, high disposable income, transforming government policies specific to orphan diseases diagnosis and treatment, and rising public awareness associated with healthcare insurance and disease diagnosis.

Market Competition Assessment:

The acquired hemophilia treatment market is observed to be majorly dominated by few players operating in the market.  The market is dominated by players, depending on their major competencies. The key players in this market are Baxalta, Inc. (Shire), Novo Nordisk, Biogen, Pfizer, Inc., and F. Hoffman La Roche. 

Key Market Movements:

• Acquired hemophilia represents a life threatening bleeding disorder, particularly in the geriatric population. Hence, rising geriatric population globally is a major driving factor.
• There is an increasing adoption of prophylaxis in hemophilia patients, currently standing at 25% to 30%. Thus growing demand for prophylaxis strategies would act as a driving factor in the near future.
• The key challenge faced in acquired hemophilia treatment market is limited availability and accessibility of novel drugs in the developing nations.